Alphamab Oncology Co. Ltd. generated $100 million from a series A financing.

Camel-IDS NV said it secured €37 million (US$41.8 million) in a series A round.

Centrexion Therapeutics Corp., which filed to sell up to 5 million shares in the price range of $14 to $16 in an IPO, has postponed the offering.

Inflazome Ltd. raised €40 million (US$45.3 million) in a series B round.

Xoma Corp. said it has begun a rights offering that aims to raise approximately $20 million in gross proceeds.


Alvotech ehf. licensed rights to its biosimilar portfolio in Japan to Fuji Pharma Co. Ltd., which will be responsible for Japanese registration and commercialization of the undisclosed assets.

Bioblast Pharma Ltd. plans to acquire immunotherapy-focused Enlivex Therapeutics Ltd., which is developing an autologous and allogeneic drug pipeline for immune system rebalancing.

Immunicum AB entered a collaboration with Merck KGaA and Pfizer Inc. to evaluate its lead product, ilixadencel, in combination with Bavencio (avelumab), a human anti-PD-L1 monoclonal antibody, in a phase Ib/II trial.

Immunocore Ltd. signed a new agreement with Roche Holding AG subsidiary Genentech Inc. around IMC-C103C, a soluble T-cell receptor product targeted at melanoma-associated antigen A4-expressing solid tumors.

Leo Pharma A/S signed a deal with Pellepharm Inc. that could be worth up to $760 million. It will focus on testing patidegib topical gel for the prevention and treatment of Gorlin syndrome.

Roivant Sciences Ltd. will pay Intron Biotechnology Inc. up to $667.5 million for global rights to tonabacase (SAL-200), an experimental therapy for treating infectious diseases caused by antibiotic-resistant staphylococci.

Sinclair Pharma Ltd. closed its acquisition by Huadong Medicine Co. Ltd. for approximately $222 million.

Zenith Epigenetics Ltd. signed a clinical trial collaboration with Pfizer Inc. to evaluate the safety and efficacy of a combination of Zenith’s investigational bromodomain and extra-terminal domain inhibitor, ZEN-3694, and Pfizer’s PARP inhibitor, talazoparib, in patients with locally advanced or metastatic triple-negative breast cancer.

…And More

Astrazeneca plc reported that, for people with metastatic non-small-cell lung cancer, neither the anti-PD-L1 antibody Imfinzi (durvalumab) nor a combination of that drug with the anti-CTLA-4 candidate tremelimumab improved overall survival vs. standard-of-care chemotherapy for previously untreated patients in a phase III trial.

Australia is rolling out a nationwide electronic health record (EHR) portal, called My Health Record under which patients will be able to access their health data any time and take it with them when they move.

Biological drugs – monoclonal antibodies, peptides, recombinant proteins and the like – now account for more than 30 percent of all FDA approvals, according to a new study from the Tufts Center for the Study of Drug Development.

Swedish Orphan Biovitrum AB and Novimmune SA won an on-time FDA approval for the ultra-rare disease therapy Gamifant, for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis.